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Summary and Keywords

Objectives Randomized studies in drug resistant epilepsy (DRE) typically involve addition of
a new anti-seizure medication (ASM). However, in clinical practice, if the patient is already
on multiple ASMs then substitution of one of the current ASMs commonly occurs, despite
little evidence supporting this approach.

Methods Longitudinal prospective study of seizure outcome after commencing a previously
untried ASM in DRE patients. Multivariable time-to-event and logistic regression models
were used to evaluate outcomes by whether the new ASM was introduced by addition or
substitution.

Results 816 ASM changes in 436 adult DRE patients between 2010 and 2018 were analyzed.
The new ASM was added on 407 (50.1%) occasions and substituted on 409 (49.9%). Mean
patient follow-up was 3.2 years. Substitution was more likely if the new ASM was enzymeinducing or in patients with a greater number of concurrent ASMs. ASM add-on was more
likely if a GABA-agonist was introduced or if the patient had previously trialed a higher
number of ASMs. The rate of discontinuation due to lack of tolerability was similar between
the add-on and substitution groups. No difference between the add-on and substitution ASM
introduction strategies was observed for the primary outcome of >50% seizure reduction at
12 months.

Significance: Adding or substituting a new ASM in DRE has the same influence on seizure
outcomes. The findings confirm that ASM alterations in drug resistant epilepsy can be
individualized according to concurrent ASM therapy and patient characteristics.
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Key Findings



Number of current anti-seizure medications (ASMs) and clinician preference were the
most important factors in choosing new ASM substitution over addition.



ASM introduction by add-on or substitution did not influence seizure outcomes.



ASM discontinuation due to side effects was no different between the two groups.
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Introduction

The cornerstone of the medical management of drug resistant epilepsy (DRE) is sequential
alteration of anti-seizure medication (ASM), aiming for seizure freedom and improved
quality of life. Although the availability of multiple new ASMs has not resulted in a
significant improvement in overall prognosis1, a small but important minority of DRE
patients eventually become seizure free after continued changes to ASM treatment2-4.
Commencing a previously unused ASM is a routine part of management of DRE, but there is
relatively little data on how this should be approached and the “art” of rational polytherapy
continues to be based on clinician preference and past successes5-7.

Although multiple factors influence the choice of the ASM including seizure type, epilepsy
syndrome, patient-based factors and concurrent ASMs/other medications, an important
decision is whether to add the new ASM to the existing ASM combination or to substitute it
for one of the ASMs currently being taken. Efficacy data for new ASMs in DRE are based on
add-on randomised controlled trials,8 but in clinical practice the addition of a new ASM may
not be possible because of the side effects of the combined drug load, adverse
pharmacokinetics or other issues, and substitution is recommended. This decision involves
balancing the risk of a significant exacerbation of seizures after discontinuing a potentially
useful ASM or ASM combination, perhaps only becoming apparent with ASM withdrawal,
versus the risk of side effects and premature cessation of the newly-introduced and
potentially helpful ASM because of poor tolerability due to the accumulated drug load.

The aims of this study were to a) identify patient and clinical factors associated with the
decision to introduce ASM by addition or substitution, b) to assess the retention of the
introduced ASM and how this varied by method of introduction and c) to assess whether
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method of ASM introduction influenced seizure response, tolerability and mortality
outcomes.

Methods

1. Study design
This was a longitudinal prospective study of patients attending a single epilepsy service
between 2010 and 2018. To be eligible, patients needed to have epilepsy of at least two years
duration, to have failed two or more ASMs, and with disabling and countable seizures
occurring at least once a month. Detailed socio-demographic and clinical information was
systematically recorded at the time of enrolment. Electroclinical syndrome was categorised as
focal epilepsy, genetic (idiopathic) generalized epilepsy, and developmental and epileptic
encephalopathy (symptomatic generalized epilepsy). Drop attacks were defined as tonic or
atonic seizures or unspecified seizures other than tonic-clonic seizures associated with a fall
or loss of postural tone. Epileptogenic lesions were classified as mesial temporal sclerosis
(MTS), malformations of cortical development (MCD) or other. Prior surgery included
lesionectomy, anterior temporal lobectomy (ATL), other focal cortical resections, corpus
callosotomy and vagal nerve stimulation (VNS).
Patients were followed up at regular clinic visits following all new ASM introductions. Side
effects, ASM cessations and seizure outcomes were recorded at each visit until 30th
September 2018, date of death or date of last clinic visit if lost to follow up. The study was
approved by the Royal Perth Hospital Human Research Ethics Committee (EC 2012/025).

2. Exposure measures
The exposure of interest was whether the new ASM was introduced by addition to the
existing ASM combination or whether it was substituted by withdrawing an existing ASM.
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All new ASM introductions that occurred before 30th September 2018 and with >90 days
follow-up were identified and assessed. Patients’ seizure control was assessed at each visit
and if suboptimal and dose changes of the current ASMs were constrained, then a new ASM
was offered. Substitution was defined as introduction of a new ASM with a clear and specific
plan to wean and stop a concurrent ASM. Typically, this involved titration of the new ASM
to an initial target dose without any change to the concurrent ASMs and then gradual
discontinuation of one of the concurrent ASMs. Add-on categorization required that no
specific plan to alter the concurrent ASMs was in place at the time of the introduction of a
new ASM.
The choice of drug was based on seizure type, epilepsy syndrome, clinical context, treating
doctor preferences and patient wishes. At the time of starting the new ASM, the concurrent
ASMs and doses of these documented with the baseline ASM “load” calculated as the sum of
prescribed daily dose (PDD) divided by the defined daily dose (DDD) for each co-prescribed
ASM9, 10. Patients were followed up at regular intervals, typically 1 to 3 months after each
ASM change and then further assessed every 3 to 6 months after dose optimization of the
ASM, depending on seizure outcome and tolerability. If the new ASM was effective it was
continued, and if not the new ASM was either withdrawn, substituted with another ASM or
left in place and a new ASM commenced. All patients enrolled had one or multiple separate
new ASMs introduced over the course of their follow up.
ASMs were categorised according to primary mode of action as follows: Sodium Channel
Blocker (SCB), Gamma-AminoButyric Acid (GABA) analogue, Synaptic Vesicle Protein 2A
Binding (SV2A) and Other. Introduced and concomitant ASMs were also categorised as
‘older agents’ (phenytoin, carbamazepine, benzodiazepines, valproate, phenobarbitone,
primidone, ethosuximide) and ‘newer agents’ (all others). Lastly ASMs were also classified
as hepatic enzyme inducing or non-inducing (see supporting information, table S1).
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2. Outcome measures
Tolerability and efficacy outcomes were analyzed following each ASM introduction.
Retention was assessed by the rate of ASM discontinuations due to side effects or lack of
efficacy. Side effects data were documented based on unstructured interviews at routine and
unscheduled clinical appointments following ASM introduction. Based on patient history and
seizure diaries, baseline seizure frequency was calculated as mean number of seizures per
month, averaged over the three months prior to making the ASM change. Lack of efficacy
was defined as less than a 50% reduction of seizure frequency.
The primary outcome assessed was the proportion of ASM introductions resulting in ≥50%
reduction in seizure frequency compared to baseline for 12 months or longer (responders) at
any time after introduction of the new ASM and prior to end of follow up, drug cessation or
introduction of another ASM or other epilepsy treatment. Seizure outcomes at 3 and 6 months
after ASM introduction and sudden unexpected death in epilepsy (SUDEP) and all epilepsyrelated mortality rates were also assessed for the study cohort.
3. Potential demographic and clinical confounders
The association of method of ASM introduction with seizure outcome and new ASM
retention were potentially confounded by other factors. Patient demographic and other
variables assessed were sex, age at ASM introduction, age at epilepsy onset, intellectual
disability (measured or estimated intellectual quotient less than 70) and mental health status.
Epilepsy-related variables included seizure type/s and electroclinical syndrome, whether
epilepsy was refractory from onset (no previous periods greater than six-months seizure free),
a prior history of status epilepticus, etiology of epilepsy and type of epileptogenic lesion if
known, prior epilepsy surgery and what type, occurrence of seizure clusters in the last year
and hospital admissions for seizures in the year prior to ASM introduction.
3. Statistical methodology
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Intention-to-treat (ITT) analysis was utilised with assessment starting from the time the new
ASM was added or substituted. Equality of proportions was tested with chi-square tests, and
equality of means using t-tests.
Multivariable logistic regression models were constructed to identify patient and clinical
factors associated with the odds of a) a new ASM being introduced by substitution compared
to addition and b) a ≥50% improvement in seizure outcomes for 12 months or longer. The
logistic regression models were constructed using population-averaged generalised estimating
equations to account for within-patient correlation.
Time to event (survival) analysis was used to assess factors associated with duration on the
newly introduced ASM. Kaplan-Meier survivorship functions were constructed assuming
independence between multiple ASM failures per patient and equality of survivor functions
tested with log rank tests. Multivariable time-to-event analyses were performed using flexible
parametric Royston-Parmar models with time-dependent covariates included when nonproportional hazards were present and standard errors adjusted for patient clustering. SUDEP
and all epilepsy-related mortality rates were also estimated using censor date for death being
1st May 2019.
For all regression models, plausible interaction terms were assessed for inclusion and robust
standard errors estimated. Parsimonious models, where only variables showing a statistical
association with the outcome (i.e. p <0.05) or a strong confounding effect on the method of
ASM introduction were included. All analyses were performed using Stata 15 (College
Station, TX).

RESULTS

436 patients were enrolled and collectively underwent 822 ASM introductions, 816 of which
had at least 90 days follow-up and were included in the study. The cohort comprised a highly
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refractory group of adults with DRE, with median duration of epilepsy of 21 years and
median number of six prior ASMs (Table 1).

Of the 816 ASM introductions 407 (49.9%) were by substitution and 409 (50.1%) were added
on. 229 patients had exclusively 1 ASM change during the period of follow-up, 115 patients
had 2 ASM changes and 92 patients had 3 or more ASM changes (totalling 357 drug trials).
The proportion substituted or added was similar irrespective of whether it was the first,
second or third or more ASM introduced. Twenty-five different ASMs were introduced
during the study; however most (85.9%) involved one of ten drugs (lacosamide, clobazam,
zonisamide, perampanel, levetiracetam, lamotrigine, topiramate, carbamazepine, phenytoin
and valproate in decreasing order, see supporting information, figure S1). Of all ASM
introductions, 742 (91%) attained the initial planned target dose, and was slightly less
frequently achieved when the new ASM was added (87% versus 93%). Of the most
frequently introduced ASMs, substitution was most commonly employed for carbamazepine
(82%, p<0.001), zonisamide (62%, p=0.010) and lacosamide (58%, p= 0.033) whereas
addition was most commonly used for clobazam (74%, p < 0.001) (Figure S1 supporting
information).
Factors associated with substitution versus addition of new ASM
Cross-tabulation of patient, doctor and temporal variables with mechanism of ASM
introduction are shown in table S2 of the supporting information. Multivariable regression
analysis adjusting for other covariates found the method of introduction varied significantly
between the three treating doctors, with over three times the odds of substitution for one
doctor compared to another (Table 2). Other factors significantly associated with increased
odds of substitution were increasing number of current ASMs and having an enzyme
inducing ASM introduced. Factors associated with new ASM introduction by add-on were
the use of a GABA analogue and increasing numbers of previously trialled ASMs.
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Patient age at time of ASM change, age at onset of epilepsy, sex, presence of psychiatric
issues, intellectual disability, electroclinical syndrome, prior history of status epilepticus or
seizure clusters, prior surgery, admission for epilepsy in last 12 months and presence of an
epileptogenic lesion were not associated with the decision to add-on or substitute the new
ASM after taking other factors into account.

ASM tolerability and retention with method of introduction
The new ASM was stopped in 366 (45%) of all ASM introductions, predominantly due to
side effects (n=128; 35%) or lack of efficacy (n=224; 61%) with a small number for other
reasons (n=14; 4%, see supporting information table S3). Of the 10 most frequently
introduced ASMs, Zonisamide, Perampanel and Topiramate were stopped more frequently
for side effects while Lacosamide and Perampanel were most frequently stopped due to lack
of efficacy (Table S3 supporting information).

Time to event analysis was used to assess both the timing and occurrence of discontinuing
newly introduced ASMs. Overall, the median duration on new ASM was 3.2 years. New
ASM retention at 3, 6 and 12 months was 85%, 76% and 60% respectively. When stratified
by method of introduction, the median duration on new ASM substituted was 6.5 years
compared to 1.8 years for added ASM (figure 1, log rank p-value 0.003). When restricted to
discontinued ASM (n=366) and stratified by reason for stopping (figure S2 supporting
information), the median duration for ASM stopped due to side effects was 62 (IQR 20-139)
days compared to 251 (IQR 133-473) days for ASM stopped due to lack of efficacy (log rank
p-value <0.001).
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Multivariable survival regression analysis assessed whether the association between method
of ASM introduction and duration on ASM remained after taking positive seizure outcome
and other factors into account (see supporting information Table S4). After accounting for
other covariates, the rate of discontinuation remained 38% (95%CI 11%-69%) higher in
ASMs introduced by addition compared to substitution. Tests for interaction terms indicated
that association of method of introduction with duration on ASM did not vary by levels of
other covariates.

Other factors (Table S4) independently associated with earlier discontinuation of a new ASM
were having <50% improvement in seizures, being female, and being commenced on
perampanel. Females were more likely to stop the new ASM than males (48% vs 41%) with
weak statistical evidence (equality of proportions, chi square p=0.06). Of patients who
stopped their ASM due to any reason, females were more likely to discontinue due to side
effects (1.6 ORCI 1.0 – 2.4) compared to males, after adjusting for other significant
factors. There was no relationship between sex and discontinuation because of lack of
efficacy. Introduction of carbamazepine or clonazepam was associated with higher retention
rates when compared to all other drugs combined. There was no evidence that number of
current ASMs or total ASM load as assessed by PDD/DDD ratio at the time of new ASM
introduction was associated with the rate of discontinuation of a new ASM in the
multivariable model (see supporting information figures S3 and S4).
For the new ASM introductions that were stopped because of lack of efficacy or side effects
(n=352), time-to-event regression models were used to assess whether the method of
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introduction modified the association between duration on ASM and reason stopping after
taking other covariates into account. Overall, the average rate of discontinuation was 3.3
(95% CI 2.4 – 4.5) times faster for side effects compared to lack of efficacy (see figure S2
supporting information), however this varied by the method of introduction (interaction pvalue= 0.035). For all ASM stopped due to lack of efficacy (figure 2), those introduced by
add-on were stopped 40% earlier (HR 1.4; 95%CI 1.1-1.8) than ASM introduced by
substitution whereas for ASM stopped due to side effects, there was no difference in duration
by the method of substitution (HR 0.9; 95%CI 0.6-1.3).

Seizure outcome.
There were 718 ASM introductions with enough follow up to estimate seizure outcomes at 12
months. There was no difference in the proportion of responders (≥50% reduction of seizures
over 12 months or more) by method of ASM introduction (p=0.933) (figure 3), with 89
(25.1%) responders amongst all ASM additions and 92 (25.3%) responders amongst all ASM
substitutions. Similarly, there was no difference in the proportion of patients with > 50%
reduction of seizures for 3 and 6 months by method of introduction (p=0.057 and p=0.668
respectively.

Multivariable analysis showed the lack of association between method of ASM introduction
and seizure outcome remained after taking other patient factors into account (Table 3). Sex,
age at ASM change and age at onset of epilepsy by either method of ASM introduction did
not influence efficacy outcomes. Higher odds of improved seizure outcomes after new ASM
introduction were observed for patients who reached the new ASM target dose and those with
a prior history of seizure-free periods. Reduced odds of improved seizure outcomes were
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observed in patients with an increasing number of previous ASMs tried and for topiramate as
the newly introduced ASM.

Worsening of seizures.

63 ASM introductions (8%) were associated with a worsening of seizures within 180 days of
commencing a new ASM, with no significant difference between the two groups (36 added
and 27 substituted p = 0.245 chi square test).

Mortality
There were 22 (5%) deaths recorded during follow-up, with SUDEP in nine patients
(4.4/1000 patient years, 95% CI 2.3-8.4), other epilepsy-related causes in six patients and
death from unrelated causes in seven patients. SUDEP occurred in six patients with last ASM
change being add-on and in three patients in whom there had been a substitution but the study
was insufficiently powered to detect any clinically meaningful difference in death rates by
method of ASM introduction.

DISCUSSION

In our study new ASMs were introduced by substitution and addition equally. Comparison of
the two strategies showed no difference for efficacy outcomes, with a quarter achieving at
least a 12 month period of 50% or greater seizure reduction in both groups, and with 6%
achieving seizure freedom for at least 12 months, seizure outcomes comparable to those seen
in randomised and observational studies2-4, 8, 11. Although physician differences in using one
strategy over another were present, these were not associated with any difference in seizure
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outcomes, providing reassurance that individual preference of ASM and method of
introduction may be less important than previously thought5-7. SUDEP rate in the cohort is
comparable to previous DRE cohorts12 and did not seem to differ according to method of new
ASM introduction.

Severity of epilepsy as measured by number of prior ASMs was a strong predictor of a poor
seizure outcome as consistently shown in prior studies2-4. Reaching an optimized target dose
significantly improved seizure control, as shown previously in one study where
improvements occurred after increasing ASM dose if it was below 50% of DDD13. We did
not identify any single ASM to be associated with a greater likelihood of a ≥50% reduction in
seizures. However, newly introduced Topiramate was associated with a lower likelihood of
≥50% reduction in seizures, in contrast to randomized trials of DRE that demonstrated
topiramate efficacy14 but concordant with a pragmatic open label study showing that
topiramate monotherapy was inferior to other ASMs in both focal and generalised epilepsy15,
16

.

In accordance with typical practice in DRE management, the decision how to introduce a new
ASM was largely based on patient and ASM factors but was also highly physician
dependent3,5. We did not find that age and sex influenced the decision to favor substitution
over addition despite the potential for the elderly and women of reproductive age to be more
prone to adverse effects of polytherapy5, 17. Benzodiazepines were preferentially introduced
as add-on treatment, consistent with their recommended use18. A history of a greater number
of prior ASMs was associated with addition rather than substitution of the new ASM, likely
reflecting a relative greater severity of epilepsy and lower response rate in these patients as
consistently seen in observational studies of DRE2, 19.
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Number of concurrent medications was also associated with method of ASM introduction,
substitution being more likely if the patient was on a higher number of concurrent ASMs, but
ASM burden as measured by PDD/DDD ratio was not independently associated with
increased odds of substitution.

Although one of the strongest predictors for continuing a new ASM is improved seizure
control, we found a lower likelihood of early ASM discontinuation with new ASM
substitution compared to addition irrespective of seizure outcome. This appears to be
independent of both number of concurrent ASMs and dose burden (as determined by
PDD/DDD ratio) as shown in an observational study of lacosamide introduction20. However
whilst the rate of ASM withdrawal was higher in the add-on group, this was not attributable
to a difference in the discontinuation rate due to side effects. This finding is congruent with
other studies which show that adverse events are more linked to patient susceptibility, type of
ASMs used and physician approach including rate of new ASM introduction rather than
number of co-prescribed drugs or ASM load9. Furthermore it is likely that clinicians have a
lower threshold to discontinuing a newly introduced ASM that has been added and is
ineffective or is associated with minor side effects because new ASM cessation simply means
a return to baseline treatment. In contrast, withdrawal of a new substituted ASM may be less
straightforward because, unless the old ASM is recommenced, the patient will be on less than
their baseline treatment. This likely explains the apparent higher rate of discontinuation in the
add-on group, and is supported by the finding of a much earlier withdrawal of new ASM
introduced by addition as compared to substitution. We also found that females had a higher
rate of ASM discontinuation than males, concordant with previous prospective observational
studies21-23. Higher Adverse Event Profile questionnaire scores were reported in females by
Canevini et al9 and the SANAD trial23 found that females had a significantly higher rate of
unacceptable adverse events and associated treatment failure. Furthermore analysis based on
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administrative claims data looking at persistence of therapy based on prescription patterns
found ASM combinations containing SCB in females to have a higher HR of discontinuation
(HR 1.057, p = 0.05) but not GABA analogue combinations24. Another study found a hgher
rathe of unacceptable cosmetic side effects of ASMs in females which may also contribute to
a higher rate of discontinuation

25

. In contrast, we found that age at ASM change was not a

predictor of discontinuation, in particular older patients were no more likely to discontinue
the new ASM due to side effects, irrespective of how the ASM was introduced. Furthermore
neither age or sex predicted seizure outcomes, in line with other prospective and
observational studies of DRE 2-4, 13, 26.

The optimal method of new ASM introduction in DRE in clinical practice has not been well
studied, with almost all randomized clinical trials on new ASMs utilizing an add-on design as
required to assess efficacy and meet regulatory approval guidelines8. Trials using substitution
have been less commonly employed for drug approvals (‘conversion to monotherapy’ using
placebo, pseudo-placebo or historical-control group comparators)27-29. These trial designs,
despite their shortcomings, provide evidence of efficacy of a substitution approach in DRE
and have led to several ASMs being approved for use as monotherapy. Randomized studies
comparing add-on to substitution in relatively newly diagnosed focal epilepsy patients failing
initial ASM monotherapy have shown no difference in seizure outcomes30,

31

but some

observational studies suggest substitution is associated with better seizure outcome and
retention rate32. Prospective observational studies assessing remission in DRE cohorts do not
explicitly analyze seizure outcomes by mode of drug introduction2,

3

but one recent

longitudinal cohort study showed no differences in the two approaches26.

This was a pragmatic observational study without randomized allocation of the method of
ASM introduction, but our data suggest that a major difference in the method of new ASM
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introduction and seizure outcome is unlikely. A randomized study of add-on versus
substitution with systematic evaluation of quality of life, seizure outcomes and adverse
effects would be optimal. Other limitations of this study include crossover ASM change
analysis rather than single drug changes in individual patients. Whilst the results were similar
for those patients having one ASM change compared to multiple ASM changes, 21% of our
patients had three or more ASM changes during the study period, consistent with the high
rate of severe DRE in the study cohort which could have masked a possible difference in
seizure outcome between addition and substitution that may be identified in less drugresistant patients.

Furthermore although our study documented side effects prospectively at routine and
scheduled clinical appointments, this was based on unstructured interviews rather than a
structured questionnaire. A systematic and potentially blinded ascertainment of side effects
could have altered discontinuation analysis; for example, it is possible that patients with addon new ASM experienced more side effects or alternatively physicians and patients were
biased towards stopping the new add-on ASM even when similar side effects occurred
following introduction of a new ASM by substitution. When evaluated systematically adverse
effects of ASMs are more likely to be detected33 and may provide a more inclusive patient
experience of polytherapy, although this approach may not improve health outcomes34.

Conclusions

We have found that the method of introduction of a new ASM in adults with highly refractory
DRE is not a major factor in determining seizure outcomes. Our findings support an
individualised approach, with decisions to add or substitute a new ASM according to patient
characteristics and concurrent ASM therapy.
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Figure legends
Figure 1. Survivorship function showing duration on ASM stratified by method of
introduction (n=816)
Figure 2 Method of introduction and reason for discontinuation in the subset of new ASM
stopped (n=352).
Figure 3 Seizure Outcomes at 3, 6 and 12 months.
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Supporting information word document

1. Anti-seizure medication (ASM) drug details
a. Classification of ASMs by mechanism of drug action (TableS1)
b. Absolute numbers of added or substituted ASMs (Figure S1)
2. Factor associated with substitution versus addition of new ASM (Table S2)
3. Drug discontinuation analysis
a) New ASMs and reasons for discontinuation (Table S3)
b) Relative adjusted hazard rate of stopping new ASM by method of
introduction (Table S4.)
c) Survivorship function for ASM discontinuation by method of introduction
and reason for discontinuation of new ASM (n=366) (Figure S2)
d) Drug burden frequency distribution (figure S3) and survivorship function
based on PDD/DDD ratio quintiles (Figure S4)
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